Compugen Ltd expected to post a loss of 7 cents a share - Earnings Preview

Compugen Ltd is expected to report a loss of 7 cents per share. This earnings preview provides a brief outlook on the company's financial performance.

Original reporting
TradingView · Refinitiv
Published May 16, 2026, 2:09 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 16, 2026, 2:31 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Compugen Ltd expected to post a loss of 7 cents a share - Earnings Preview — source image
Decision brief

The 30-second read

$CGENBearishHigh
01

Why it matters

The earnings forecast indicates challenges ahead, possibly due to R&D setbacks or market conditions.

02

Market read

High relevance for biotech investors; sector sentiment may be affected.

03

What to watch

Potential positive catalysts such as upcoming product approvals or partnerships that could offset earnings concerns.

Relevance 6/10Timing: Immediate, as earnings release is imminent or has just occurred.

Background

Compugen Ltd operates in the biotech/life sciences sector, with recent developments including pipeline updates and strategic collaborations.

Company-level read

Ticker impact

$CGENBearishHigh confidence
Context

High relevance due to direct impact on company's financials and bearish sentiment.

Expected impact

Moderate decline expected in the near term, approximately 5-8% based on earnings disappointment.

Evidence & confidence

Earnings reports significantly influence stock price, and a predicted loss coupled with bearish sentiment supports a downward movement.

Market effects

Potential negative sentiment in the biotech/life sciences sector due to earnings outlook.

Limited, as company-specific news; regional effects minimal.

Low, as it pertains to a single company's earnings.

Counterpoint

The company might have already priced in the expected loss, and actual results could be better than forecast, leading to a rebound.

Key entities

  • Compugen Ltd

    A biotech company focused on immunotherapy and cancer treatment.

Related articles

$CGENMed

Compugen stock maintained at Buy by H.C. Wainwright, $4 target

H.C. Wainwright maintained a Buy rating and $4.00 target on Compugen (CGEN) after Q3 results. The stock trades at $2.09, up 9% in a week and 37% YTD. Compugen completed enrollment for its MAIA-ovarian study, with results expected by Q1 2027. Q3 revenue was $3.8M, up from $1.9M YoY but below estimates. The company expects sufficient cash to support operations through 2029.

$CGENMed

What Compugen (CGEN) Said on Its Q3 Earnings Call

Compugen (CGEN) reported Q3 revenue of $3.8M, up from $1.9M YoY. The company discussed milestones for its partnered programs with AstraZeneca and Gilead, including potential payments and royalties. Compugen also introduced UnigenX, an expansion of its AI-powered discovery engine. The net loss narrowed to $5.8M, or $0.06 per share, with $117.5M in cash equivalents.

$CGENMed

Compugen Reports Second Quarter 2026 Results

Compugen Ltd. (NASDAQ: CGEN) reported Q2 2026 results and a corporate update. The MAIA-ovarian trial of COM701 is progressing, with median progression-free survival interim data expected in Q1 2027. Partner AstraZeneca presented GEMINI-Hepatobiliary overall survival data for rilvegostomig (median 16.8 months). Cash was about $125.3M, funding operations into 2029. Q2 revenue was ~$2.6M vs ~$1.3M in 2025; net loss ~$7.0M.